

A woman in her late fifties undergoes TAH/BSO and is found to have an 8.9-cm, high-grade uterine leiomyosarcoma with negative margins. What metastatic workup would you recommend?



Would you recommend pelvic lymphadenectomy for the patient in the previous scenario?


Yes

9%



No

85%



I don't know

6%



The patient in the previous scenario undergoes metastatic workup, which is negative. What adjuvant therapy, if any, would you recommend?



How frequently do you administer neoadjuvant chemotherapy to your patients with large but localized uterine leiomyosarcoma?

Very frequently

6%



Occasionally

14%




Rarely

30%



Never

50%



How frequently do you administer neoadjuvant radiation therapy to your patients with large but localized uterine leiomyosarcoma?

Very frequently

1%

Occasionally


12%

Rarely


33%

Never

54%



A woman in her midforties presents with vaginal bleeding and an enlarged uterus. CT scan reveals a large uterine mass and a single lesion in the right hepatic lobe. Biopsies of both the liver and the uterus confirm leiomyosarcoma. What would be your initial approach to therapy?




A woman in her fifties presents with vaginal bleeding and is found to have a 5.3-cm, ER/PR-positive uterine leiomyosarcoma with diffuse severe atypia, coagulative tumor cell necrosis and a mitotic rate of 27/20 HPF. What adjuvant therapy, if any, would you recommend?




The patient in the previous scenario does not wish to receive adjuvant chemotherapy but would consider oral endocrine therapy. Would you recommend adjuvant hormonal therapy?



Approximately how many patients with metastatic uterine sarcoma are currently in your practice?




Approximately how many patients with metastatic uterine sarcoma in your practice are currently receiving olaratumab?



A woman in her thirties undergoes TAH/BSO for high-grade uterine leiomyosarcoma and receives adjuvant doxorubicin followed by pelvic radiation therapy. One year later she presents with biopsy-proven retroperitoneal and abdominal lymphadenopathy. What systemic therapy would you recommend?



The patient in the previous scenario receives docetaxel/gemcitabine and achieves a partial response for 9 months followed by progressive disease in the lungs. What systemic therapy would you recommend?



What would generally be your first-line treatment recommendation for a patient in her forties with metastatic uterine leiomyosarcoma who has not received prior systemic therapy?



What would generally be your second-line treatment recommendation for a patient in her forties with metastatic uterine leiomyosarcoma who is experiencing disease progression on a doxorubicin-containing regimen?

Docetaxel/gemcitabine

51%



Trabectedin

18%



Eribulin

5%



Pazopanib

18%



Other

8%



What would generally be your second-line treatment recommendation for a patient in her forties with metastatic uterine leiomyosarcoma who is experiencing disease progression on docetaxel/gemcitabine?



What would generally be your third-line treatment recommendation for a patient in her forties with metastatic uterine leiomyosarcoma who has experienced disease progression on doxorubicin and gemcitabine/docetaxel?

Trabectedin

34%



Eribulin

11%



Pazopanib

38%




Other

18%



Have you or would you order next-generation sequencing for a patient with recurrent metastatic uterine leiomyosarcoma?



Would you attempt to access an ALK inhibitor for a patient with recurrent metastatic uterine leiomyosarcoma who is found to have an ALK rearrangement?

Yes

51%



No

15%



I don't know

34%



Would you attempt to access a BCR-ABL tyrosine kinase inhibitor for a patient with recurrent metastatic uterine leiomyosarcoma who is found to have a c-KIT mutation?

Yes

55%



No

7%



I don't know

38%



Do you generally order MSI testing for your patients with metastatic uterine leiomyosarcoma?

Yes

33%



No

67%

